Literature DB >> 21271231

[Nosocomial pneumonia. Prevention and diagnostic].

T Perl1, M Quintel.   

Abstract

Pneumonia occurring more than 48 h after induction of mechanical ventilation is called ventilator-associated pneumonia (VAP). VAP is the most common nosocomial infection in intensive care medicine and is associated with prolonged intensive care and hospital stay and a higher mortality. The main pathomechanism for development of ventilator-associated pneumonia is not so much the mechanical ventilation per se but more the pathogens passing along the tube towards the lungs. Avoidance of tracheal intubation, strict hygienic measures, reduction of oropharyngeal colonization and the avoidance of microaspiration are the most promising prevention strategies. Therapeutic success in treatment of VAP is coupled to an early diagnosis and therapy. Suspicion of pneumonia is based on clinical and radiologic criteria. Biomarkers and microbiological findings are important for follow-up and reevaluation of the suspected diagnosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21271231     DOI: 10.1007/s00101-010-1843-2

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  35 in total

1.  [Nosocomial pneumonia: prevention, diagnosis, treatment].

Authors:  J Lorenz; K-F Bodmann; T T Bauer; S Ewig; M Trautmann; F Vogel
Journal:  Pneumologie       Date:  2003-09

Review 2.  Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis.

Authors:  Cameron Dezfulian; Kaveh Shojania; Harold R Collard; H Myra Kim; Michael A Matthay; Sanjay Saint
Journal:  Am J Med       Date:  2005-01       Impact factor: 4.965

3.  Continuous aspiration of subglottic secretions in the prevention of ventilator-associated pneumonia in the postoperative period of major heart surgery.

Authors:  Emilio Bouza; María Jesús Pérez; Patricia Muñoz; Cristina Rincón; José María Barrio; Javier Hortal
Journal:  Chest       Date:  2008-07-18       Impact factor: 9.410

Review 4.  Bundles to prevent ventilator-associated pneumonia: how valuable are they?

Authors:  Charity Wip; Lena Napolitano
Journal:  Curr Opin Infect Dis       Date:  2009-04       Impact factor: 4.915

5.  Reduction of ventilator-associated pneumonia: active versus passive guideline implementation.

Authors:  Caroline S Hawe; Kirsteen S Ellis; Chris J S Cairns; Andrew Longmate
Journal:  Intensive Care Med       Date:  2009-03-24       Impact factor: 17.440

6.  Ecological effects of selective decontamination on resistant gram-negative bacterial colonization.

Authors:  Evelien A N Oostdijk; Anne Marie G A de Smet; Hetty E M Blok; Emily S Thieme Groen; Gerard J van Asselt; Robin F J Benus; Sandra A T Bernards; Ine H M E Frénay; Arjan R Jansz; Bartelt M de Jongh; Jan A Kaan; Maurine A Leverstein-van Hall; Ellen M Mascini; Wouter Pauw; Patrick D J Sturm; Steven F T Thijsen; Jan A J W Kluytmans; Marc J M Bonten
Journal:  Am J Respir Crit Care Med       Date:  2009-12-03       Impact factor: 21.405

7.  Association of noninvasive ventilation with nosocomial infections and survival in critically ill patients.

Authors:  E Girou; F Schortgen; C Delclaux; C Brun-Buisson; F Blot; Y Lefort; F Lemaire; L Brochard
Journal:  JAMA       Date:  2000-11-08       Impact factor: 56.272

8.  Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention.

Authors:  John Muscedere; Peter Dodek; Sean Keenan; Rob Fowler; Deborah Cook; Daren Heyland
Journal:  J Crit Care       Date:  2008-03       Impact factor: 3.425

9.  Impact of patient position on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials.

Authors:  Vangelis G Alexiou; Vrettos Ierodiakonou; George Dimopoulos; Matthew E Falagas
Journal:  J Crit Care       Date:  2009-02-13       Impact factor: 3.425

10.  Early- and late-onset pneumonia: is this still a useful classification?

Authors:  Petra Gastmeier; Dorit Sohr; Christine Geffers; Henning Rüden; Ralf-Peter Vonberg; Tobias Welte
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.